cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1415Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESРоль дисфункции эндотелия в патогенезе атеросклерозаEndothelial dysfunction role in atherosclerosis pathogenesisВоробьеваЕ. Н.VorobyevaE. N.marinakhoreva@mail.ruШумахерГ. И.ShumakherG. I.marinakhoreva@mail.ruОсиповаИ. В.OsipovaI. V.marinakhoreva@mail.ruХореваМ. А.KhorevaM. A.marinakhoreva@mail.ruВоробьевР. И.VorobyevR. I.marinakhoreva@mail.ruАлтайский государственный медицинский университет. БарнаулAltay State Medical University. Barnaul20062012200656129136Copyright © Воробьева Е.Н., Шумахер Г.И., Осипова И.В., Хорева М.А., Воробьев Р.И., 20062006Воробьева Е.Н., Шумахер Г.И., Осипова И.В., Хорева М.А., Воробьев Р.И.Vorobyeva E.N., Shumakher G.I., Osipova I.V., Khoreva M.A., Vorobyev R.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1415

С современных позиций ключевым звеном в патогенезе атеросклероза считается эндотелиальная дисфункция (ЭД), которая проявляется дисбалансом между основными функциями эндотелия: вазодилатацией и вазоконстрикцией, ингибированием и содействием пролиферации, антитромботической и протромботической, антиокислительной и проокислительной. Свои эффекты эндотелий оказывает посредством выделения ряда вазоактивных веществ – вазодилататоров (оксид азота, простациклин, брадикинин) и вазоконстрикторов (эндотелин, свободные радикалы кислорода, тромбоксан А2 , ангиотензин II). Доказано, что практически все факторы риска (ФР) атеросклероза реализуют свое неблагоприятное воздействие через ЭД. В связи с этим, актуально использование показателей функции эндотелия в качестве маркеров ранних атеросклеротических изменений у лиц с ФР атеросклероза еще до появления клинических признаков заболевания. Назначение патогенетической терапии на этом этапе, а также у лиц с доказанным атеросклерозом позволит значительно улучшить прогноз пациентов.

According to modern views, the key component in atherosclerosis pathogenesis is endothelial dysfunction (ED), manifesting in dysbalance between main endothelial functions: vasodilatation and vasoconstriction, proliferation inhibition and promotion, antithrombotic and prothrombotic, antioxidant and prooxidant functions. Endothelial effects are mediated through vasoactive agents’ release – vasodilatators (NO, prostacyclin, bradykinin) and vasoconstrictors (endothelin, free oxygen radicals, thromboxan A2 , angiotensin II). It has been demonstrated that virtually all atherosclerosis risk factors (RF) realize their negative effects via ED. Therefore, endothelial function parameters could be used as early atherosclerosis markers in individuals with atherosclerosis RF, at pre-clinical stage. Pathogenetic therapy, administered early or in already verified atherosclerosis, could improve patients’ prognosis substantially.

атеросклероздисфункция эндотелияфакторы рискаэндотелиноксид азотаAtherosclerosisendothelial dysfunctionrisk factorsendothelinNOReferencesГосударственный доклад о состоянии здоровья населения Российской Федерации в 2003 году. Здравоохранение Российской Федерации 2005; 5: 3-19.Государственный доклад о состоянии здоровья населения Российской Федерации в 2003 году. Здравоохранение Российской Федерации 2005; 5: 3-19.Дудкова В.А., Карпов Р.С. Атеросклероз сосудов сердца и головного мозга. Томск: STT 2002; 416 c.Дудкова В.А., Карпов Р.С. Атеросклероз сосудов сердца и головного мозга. Томск: STT 2002; 416 c.Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: 27-32.Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: 27-32.Herrmann J, Lerman A. The endothelium: Dysfunction and beyond. J Nuclear Cardiology 2001; 8: 197-206.Herrmann J, Lerman A. The endothelium: Dysfunction and beyond. J Nuclear Cardiology 2001; 8: 197-206.Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90: 40-8.Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90: 40-8.Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-26.Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-26.Teerlink JR. Endothelins: Pathophysiology and treatment implications in chronic heart failure. Current Heart Failure Reports 2005; 2: 191-7.Teerlink JR. Endothelins: Pathophysiology and treatment implications in chronic heart failure. Current Heart Failure Reports 2005; 2: 191-7.Rich S, McLaughlin VV. Endothelial receptors blockers in cardiovascular disease. Circulation 2003; 108: 2184-90.Rich S, McLaughlin VV. Endothelial receptors blockers in cardiovascular disease. Circulation 2003; 108: 2184-90.Schulze PC, Lee RT. Oxidative stress and atherosclerosis. Current Atherosclerosis Reports 2005; 7: 242-8.Schulze PC, Lee RT. Oxidative stress and atherosclerosis. Current Atherosclerosis Reports 2005; 7: 242-8.Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: 27-33.Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: 27-33.Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346: 1999-2001.Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346: 1999-2001.Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14786 middle-aged men and women in Finland. Circulation 1999; 99: 1465-72.Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14786 middle-aged men and women in Finland. Circulation 1999; 99: 1465-72.Simon T, Jailon P. Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials. Eur Heart J 2000; G2-6.Simon T, Jailon P. Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials. Eur Heart J 2000; G2-6.Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 2001; 103: 638-42.Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 2001; 103: 638-42.Fornoni A, Raij L. Metabolic syndrome and endothelial dysfunction. Current Hypertension Reports 2005; 7: 88-95.Fornoni A, Raij L. Metabolic syndrome and endothelial dysfunction. Current Hypertension Reports 2005; 7: 88-95.John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18: 363-74.John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18: 363-74.Koschinsky ML. Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Current Atherosclerosis Reports 2005; 7: 389-95.Koschinsky ML. Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Current Atherosclerosis Reports 2005; 7: 389-95.Oliveira GH. Novel serologic markers of cardiovascular risk. Current Atherosclerosis Reports 2005; 7: 148-54.Oliveira GH. Novel serologic markers of cardiovascular risk. Current Atherosclerosis Reports 2005; 7: 148-54.Balkau B, Bertrais S, Ducimetiere P. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22: 696-9.Balkau B, Bertrais S, Ducimetiere P. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22: 696-9.Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14-22.Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14-22.Chobanian AV, Barcis GI, Black HR, et al. Seventh Report of the Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressurе. Hypertension 2003; 42: 1206-52.Chobanian AV, Barcis GI, Black HR, et al. Seventh Report of the Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressurе. Hypertension 2003; 42: 1206-52.Perticone F, Ceravolo R, PujiaA, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.Perticone F, Ceravolo R, PujiaA, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105: 2696-8.Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105: 2696-8.Вихирева О.В. Курение как фактор риска сердечно-сосудистых заболеваний: актуальность проблемы и возможности ее контроля путем лечения никотиновой зависимости (обзор литературы). Профил забол укреп здор 2003; 4: 21-7.Вихирева О.В. Курение как фактор риска сердечно-сосудистых заболеваний: актуальность проблемы и возможности ее контроля путем лечения никотиновой зависимости (обзор литературы). Профил забол укреп здор 2003; 4: 21-7.Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 971-6.Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 971-6.Lee WH, Kim SH, Lee Y, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Atheroscler Thromb Vasc Biol 2001; 21: 2004-10.Lee WH, Kim SH, Lee Y, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Atheroscler Thromb Vasc Biol 2001; 21: 2004-10.Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116: 9-16.Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116: 9-16.Бахтияров Р.З. Современные методы исследования функции эндотелия. РКЖ 2004; 2: 76-9.Бахтияров Р.З. Современные методы исследования функции эндотелия. РКЖ 2004; 2: 76-9.Corretti M, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. JACC 2000; 39: 257-65.Corretti M, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. JACC 2000; 39: 257-65.Roberts CK, Vaziri ND, Wang XQ, Barnard RJ. Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet. Hypertension 2000; 36: 423-9.Roberts CK, Vaziri ND, Wang XQ, Barnard RJ. Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet. Hypertension 2000; 36: 423-9.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации разработаны Комитетом экспертов Всероссийского научного общества кардиологов. Профил забол укреп здор 2004; 5: 7-33.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации разработаны Комитетом экспертов Всероссийского научного общества кардиологов. Профил забол укреп здор 2004; 5: 7-33.Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56: 702-6.Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56: 702-6.Sesso H, Paffenbarger R, Lee I. Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. Circulation 2000; 102: 975-80.Sesso H, Paffenbarger R, Lee I. Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. Circulation 2000; 102: 975-80.Green DJ, Maiorana A, O”Driscoll G, et al. Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol 2004; 256: 1-25.Green DJ, Maiorana A, O”Driscoll G, et al. Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol 2004; 256: 1-25.Green DJ, Walsh JH, Maiorana A, et al. Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: a pooled analysis of diverse patient population. Am J Physiol 2003; 285: 2679-87.Green DJ, Walsh JH, Maiorana A, et al. Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: a pooled analysis of diverse patient population. Am J Physiol 2003; 285: 2679-87.Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387-92.Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387-92.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Cur Treat Opt Cardiovasc Med 2005; 7: 459-66.Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Cur Treat Opt Cardiovasc Med 2005; 7: 459-66.Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenior cells. Circulation 2002; 105: 3017-24.Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenior cells. Circulation 2002; 105: 3017-24.Mancini GBJ, Henry GC, Macaya C, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.Mancini GBJ, Henry GC, Macaya C, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.Berkels R, Egink G, Marsen TA, et al. Nifedipine increases endothelial nitric oxide biovailability by antioxidative mechanisms. Hypertension 2001; 37: 240-5.Berkels R, Egink G, Marsen TA, et al. Nifedipine increases endothelial nitric oxide biovailability by antioxidative mechanisms. Hypertension 2001; 37: 240-5.Parenti A, Fillipi S, Amerini S, et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000; 292: 698-703.Parenti A, Fillipi S, Amerini S, et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000; 292: 698-703.

The authors declare that there are no conflicts of interest present.